Lung Cancer

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement

By BiotechReality Business Intelligence Desk
14 July 2026

AstraZeneca has secured exclusive worldwide rights to Zegfrovy (sunvozertinib), Dizal Pharmaceutical’s oral EGFR inhibitor for EGFR exon 20 insertion non-small cell lung cancer, in a deal worth up to $1.5 billion. The agreement strengthens AstraZeneca’s EGFR-mutated lung cancer portfolio ahead of potential first-line expansion.

Clinical Trials Healthcare & Pharmaceuticals News

Johnson and Johnson’s Groundbreaking Study Shows New Drug Combination Significantly Extends Survival for Asian Lung Cancer Patients

By Athulya B S
12 September 2025

A new combination therapy has been shown to be the first and only chemotherapy-free treatment to demonstrate a significant survival advantage over the current standard of care for a specific type of lung cancer prevalent in Asia.

Regulatory Approval Healthcare & Pharmaceuticals News Oncology

Lilly’s Olomorasib Granted U.S. FDA Breakthrough Therapy Designation for Advanced Lung Cancer

By Athulya B S
4 September 2025

Eli Lilly announced its novel cancer drug, olomorasib, has been granted Breakthrough Therapy designation by the U.S. FDA. This significant milestone aims to expedite the development of the treatment for patients with advanced KRAS G12C-mutated non-small cell lung cancer, a historically difficult-to-treat condition.

Tag: Lung Cancer

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement

Johnson and Johnson’s Groundbreaking Study Shows New Drug Combination Significantly Extends Survival for Asian Lung Cancer Patients

Lilly’s Olomorasib Granted U.S. FDA Breakthrough Therapy Designation for Advanced Lung Cancer

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement